培米替尼是靶向药吗？

In April 2020, the FDA accelerated the approval of the marketing application of pemetinib for the treatment of patients with previously treated advanced cholangiocarcinoma with FGFR2 gene fusion/rearrangement. Is it a targeted drug?

Pemetinib is a targeted drug; as the first targeted drug for cholangiocarcinoma, pemetinib is expected to change the clinical treatment landscape for patients with cholangiocarcinoma.

The approval of pemetinib was based on the FIGHT-202 clinical trial. The trial results showed that among 107 patients with FGFR2 fusion/rearrangement, all patients responded to treatment. The overall response rate of pemetinib monotherapy was 36%, including 2.8% complete response and 33% partial response; the disease control rate was 82%. The median duration of response was 9.1 months; 63% of patients achieved response for 6 months or longer, and 18% maintained response for 12 months or longer.

The above data show that when pemetinib is used as a second-line treatment for cholangiocarcinoma with FGFR2 fusion/rearrangement, 82% of patients have tumors under control, and 33% of patients have significant tumor shrinkage or improvement.

It is worth noting that the overall survival (OS) has not yet been reached at the time of data cutoff, but the median overall survival (OS) of pemetinib is 21.1 months. Studies have shown that the historical average survival time of patients with second- and third-line treatments in the past was 6-7 months. This means that the second-line treatment with pemetinib has extended the survival of patients by more than three times!

In addition, the researchers stated that there were no uncontrollable adverse reactions during the study, and the severity of most adverse events was grade 1 or 2.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: